Summary
Nicotinic acid adenine dinucleotide phosphate (NAADP) is the most potent Ca2+ mobilizing second messenger that has been identified. We have previously shown that NAADP analogs substituted at the 5-position of nicotinic acid were recognized by the sea urchin receptor at low concentration, whereas the 4-substituted analogs were not as potent. However, to date the structure activity relationship (SAR) of these analogs has not been addressed in mammalian systems. Thus, we asked whether these structurally modified analogs behave similarly in an NAADP-responsive mammalian cell line (SKBR3) using microinjection and single cell fluorescent imaging methods. Novel “caged” 4- and 5- substituted NAADP analogs that were activated inside the cell by flash photolysis resulted in Ca2+ mobilizing activity in SKBR3 cells in a concentration dependent manner, but with reduced effectiveness compared to unmodified NAADP. The SAR in mammalian SKBR3 cells was quite different from that of sea urchin and may suggest that there are differences between NAADP receptors in different species or tissues. Importantly, these data indicate that modifications at the 4- and 5-position of the nicotinic acid ring may lead to the development of functional photoaffinity labels that could be used for receptor localization and isolation in mammalian systems.
Keywords: NAADP, Structure-Activity Relationships, Antagonists, Caged-NAADP, SKBR3 cells, Ca2+ signaling
1. Introduction
Ca2+ release from intracellular stores is an important event controlling several cellular processes and regulating many different functions [1–3]. In addition to the well-known intracellular Ca2+ release mechanisms triggered by inositol-1,4,5 triphosphate (IP3) and cyclic ADP-ribose (cADPR), that target inositol triphosphate and ryanodine receptors (RyR) on the endoplasmic reticulum, respectively [4–7], nicotinic acid adenine dinucleotide phosphate (NAADP) has emerged as the most potent Ca2+ mobilizing messenger [8]. NAADP was originally discovered as a contaminant of commercial NADP [9] and introduced as a Ca2+ releasing messenger in sea urchin eggs active at nanomolar concentrations [10]. Later, NAADP-dependent Ca2+ mobilizing activity was observed in different cell types and mammals including pancreatic acinar cells [11], heart [12], brain [13], kidney [14], lymphocytes [15], and human transformed Jurkat T cells [16]. In contrast to Ca2+ release in response to IP3, the nature of the NAADP targeted intracellular Ca2+ store as well as the identity of its receptor is not established [17]. For example, NAADP-induced Ca2+ release has been shown to differ in many ways from either IP3 or cADPR-mediated Ca2+ release [10, 16, 18–20]. Most available evidence suggests that NAADP-induced Ca2+ release occurs from a different subcellular compartment than does Ca2+ release in response to IP3 or cADPR [21]. Unlike canonical Ca2+ releasing messengers, NAADP mobilizes Ca2+ from acidic stores [22–24] although it appears to crosstalk with canonical intracellular channels or directly release Ca2+ from the ER in some cells [25, 26].
Because NAADP signaling is found in a diverse array of species and tissues, it is possible that the receptor differs according to its source. In addition, the structural features of NAADP required for agonist recognition are only now being defined [27]. A recent study showed that substitution at the 4-position of the nicotinic acid resulted in the loss of agonist potency for both Ca2+ release and ligand binding in sea urchin egg homogenates, whereas substitution at the 5-position was tolerated [28]. The structural features of NAADP which are necessary for receptor recognition have been best characterized in sea urchin egg homogenates, and include the adenosyl-2′-phosphate, the purine-6-nitrogen, and the pyridine-3-carboxylate [29, 30]. In mammalian cells, the structure activity relationship (SAR) for NAADP recognition is virtually unknown due to the impermeability of NAADP and to the absence of robust cell-free preparations [31]. Only one NAADP analog has so far been tested, the 5-N3-NAADP reported to be active in cultured human cells by microinjection [32]. In this report, we have synthesized inactive “caged” NAADP analogs [33, 34] that are activated inside the cell by flash photolysis and characterized their ability to mobilize Ca2+ via the NAADP receptor in the mammalian cell line SKBR3 using microinjection and single cell fluorescent imaging methods.
2. Results
2.1 Synthesis and characterization of caged NAADP derivatives
NAADP is highly negatively charged and cannot cross the plasma membrane of intact cells in the absence of pores or a specific transport system. Also, direct microinjection of NAADP requires specialized apparatus, and may cause an injection artifact which can skew experiment results if the response is monitored simultaneously with injection. Moreover, receptor desensitization by sub-threshold concentrations might occur as a result of unequal distribution of NAADP throughout the cell. This poses immense difficulties in experiments to investigate its role in its natural environment and to understand the underlying mechanism of NAADP/Ca2+ release. For these reasons, the use of inactive photolabile caged NAADP that can be activated when necessary by photolysis is the ideal molecular tool for more controlled delivery and investigation of NAADP. To achieve this goal, we have begun using caged NAADP (1), in which a 1-(4,5-dimethoxy-2-nitrophenyl)ethyl caging group is attached as an ester to the adenosyl-2′-phosphate. The synthesis of (DMNPE)-NAADP was based on a previously published study [33] (Fig. 1) and involved reaction of the 2′-phosphate of NADP with 4,5-dimethoxy-2-nitrophenyl diazoethane (DMNPE) yielding caged NADP. This was converted to the caged NAADP (1) by enzyme catalyzed exchange of nicotinic acid for nicotinamide using the activity of Aplysia californica ADP-ribosyl cyclase [35] to produce the corresponding caged NAADP derivatives. Since substituted nicotinic acids are readily available [28], caged NAADP derivatives 2–5 were synthesized in one step through the common intermediate DMNPE-caged NADP using enzyme catalyzed base exchange.
Although all analogs under study were esterified with the same caging group and therefore were expected to have similar photolysis rates, we investigated the possibility that the photolysis rates of these analogs might be different. Solutions of pure caged analogs of equal concentration were photolysed under controlled identical conditions using a short wave ultraviolet lamp and the resulting product mixture was analyzed by HPLC (Fig. 2A). The ratio of the amount of photolysed product to the intact analog was determined, and as expected, the uncaging efficiencies between analogs were not significantly different (Fig. 2B). The separated compounds can be differentiated by both their mobilities on anion exchange chromatography and their ultraviolet spectra (Supplementary Material Fig. S1).
To demonstrate that the caged NAADP and derivatives were unable to stimulate Ca2+ release and remained intact inside the cell, we examined Ca2+ release in sea urchin egg homogenates as previously described [36]. The addition of 93 nM caged NAADP caused no Ca2+ release by the homogenates (Fig. 2C). The addition of the same amount of caged NAADP that had been UV irradiated in a Rayonet photochemical reactor for 2 minutes caused significant Ca2+ release. Similarly, caged 5-methyl-NAADP caused Ca2+ release only after UV irradiation (Fig. 2D).
2.2 NAADP induces Ca2+ release from SKBR3
Our goal was to study the effect of chemical modification at the 4- and 5-nicotinic acid of NAADP in mammalian systems and compare it to the biological activity previously observed in sea urchin eggs. To achieve this, we used the human breast cancer cell line SKBR3, which has been previously shown to respond to NAADP [37, 38]. This system allowed us to study the effect of flash photolysis of caged NAADP on the intracellular Ca2+ concentration [Ca2+]i. To determine the concentration response–relationship, we injected a known concentration of caged NAADP into single cells and monitored [Ca2+]i fluorometrically using the calcium sensitive dye Fluo-4. Microinjection of caged NAADP at a pipette concentration as low as 10 nM followed by 8 to 10 flashes of ultraviolet light causing photorelease of NAADP elicited a Ca2+ response, whereas ultraviolet flashes of intracellular buffer alone had no effect (Fig. 3A). The stepwise nature of the fluorescence reflects accumulating uncaged NAADP with each flash of UV light. Within each experiment, the same number of flashes was used. As shown in Fig. 3B, the concentration response relationship showed a bell-shaped curve for the Ca2+ peak with an optimal caged NAADP pipette concentration at 100 nM. These data are consistent with other cellular systems and with the observation that NAADP induces Ca2+ release at low 30 – 100 nM concentrations, but desensitizes at high micromolar concentrations [10, 11, 16, 18, 39].
2.3 Extracellular calcium is not involved in NAADP signaling
After establishing that photolysis of caged NAADP evoked Ca2+ signals in a concentration dependent manner, we investigated the dependence of the evoked signals on extracellular Ca2+. To determine whether Ca2+ entry is involved in the NAADP-mediated Ca2+ response, we monitored cytosolic Ca2+ evoked by 100 nM caged NAADP in Ca2+-free medium. As shown in Fig 4 A and B, the Ca2+ signal was similar to that observed in Ca2+-containing medium and consistent with the result observed in pancreatic acinar cells [11]. This finding indicates that most of the Ca2+ was released from internal stores. It is worth noting that the response was reduced when the cells were suspended in Ca2+-free medium for a prolonged time period, greater than 15 minutes. This was likely due to a reduction in intracellular Ca2+ content of the cell during prolonged suspension in Ca2+ free medium, as has been previously reported [40].
2.4 ER contribution to NAADP-Ca2+ signaling in SKBR3
We next focused on the intracellular Ca2+ stores involved, since extracellular Ca2+ did not to play any major role in NAADP evoked signals. The major intracellular Ca2+ stores proposed to participate in NAADP-mediated Ca2+ signaling are the ER and acidic stores. We first examined the role of the ER Ca2+ store and sought to determine whether it was directly released in response to NAADP or indirectly involved through Ca2+ induced Ca2+ release. To test whether Ca2+ stored in the endoplasmic reticulum contributed to NAADP-Ca2+ signaling, we monitored the effect of photorelease of NAADP on the cytosolic Ca2+ concentration after the depletion of Ca2+ from the ER store using known inhibitors of the SERCA-ATPase pump, thapsigargin (TG) and cyclopiazonic acid (CPA). Depleting the ER store by pretreatment with CPA reduced the fluorescence associated with the NAADP response by 40 percent compared to control (Fig. 4 C and D). Similarly, depleting the ER by pretreatment with thapsigargin reduced the NAADP-induced Ca2+ response by 40 percent compared to control (Data not shown).
Previous experiments with Jurkat cells [26, 41] demonstrated a role for the ryanodine receptor in NAADP-dependent Ca2+ release. We examined the involvement of the ryanodine receptor in SKBR3 cells by pretreating the cells with tetracaine, a ryanodine receptor antagonist, prior to stimulation. Tetracaine reduced the subsequent response to NAADP by about 30% (Fig. 4 E), similar to the effect of CPA. This indicates that the ryanodine receptor is likely involved in the NAADP effect on ER release.
To support our observation that the ER is in fact contributing to the NAADP-induced Ca2+ signal, we indirectly examined the level of Ca2+ content in the ER before or after a response to NAADP uncaging. For example, we compared the rise in intracellular Ca2+ concentrations induced by CPA applied before or after the photorelease of NAADP. When NAADP was photoreleased prior to CPA application, the response to CPA was reduced by about 50% compared to the response when CPA was applied prior to photorelease (data not shown). Consistent with this observation, extracellular application of 100 μM ATP to activate ER Ca2+ release before the photorelease of NAADP induced robust Ca2+ signals in control cells, but the ATP-evoked signal was diminished when applied following the photolytic release of NAADP (Fig. 4F). This suggests that some ATP sensitive stores are reduced by NAADP induced Ca2+ release. Together these data indicate that a portion of Ca2+ released in response to NAADP uncaging was from the ER.
2.5 Acidic stores are the dominant source of NAADP evoked Ca2+ release in SKBR3
Since the depletion of Ca2+ from ER stores did not eliminate the signal, we investigated the role of endosomes and lysosomes in the NAADP-mediated Ca2+ release. We depleted the endo-lysosomal Ca2+ using the vacuolar proton pump (H+-ATPase) inhibitor bafilomycin A1 (confirmed by loss of Lysotracker Red accumulation, not shown) and monitored [Ca2+]i after the injection of an optimal caged NAADP concentration (100 nM) and photolysis. The Ca2+ signal observed following bafilomycin treatment was greatly reduced (five-fold lower than the control response) as shown in Fig. 5 A and B. These results are consistent with previous data from SKBR3 [37, 38] and indicate that the Ca2+ store mobilized by NAADP was reduced by the depletion of Ca2+ from the endo-lysosomal lumen. Thus, lysosome-like acidic stores appeared to be the dominant source of NAADP evoked Ca2+ release in SKBR3.
2.6 BZ194 antagonizes NAADP-mediated Ca2+ in SKBR3
We also investigated the effect of the NAADP antagonist BZ194 on the response induced by the photorelease of NAADP to confirm that the Ca2+ signals are indeed mediated by NAADP. BZ194 was reported to antagonize NAADP-mediated Ca2+ signaling via the type 1 ryanodine receptor in Jurkat T lymphocytes [26]. The response of SKBR3 cells to NAADP was diminished when 100 μM of BZ194 was co-injected along with the optimal concentration of caged NAADP (Fig. 6A). The inhibition by BZ194 of the NAADP response was concentration dependent (Fig. 6B) which provides evidence that the Ca2+ signals are due to the photorelease of NAADP. Interestingly, BZ194 did not inhibit NAADP-mediated Ca2+ release (Fig. 7 A and B) nor demonstrate any binding affinity for the NAADP receptor in sea urchin egg homogenates (Fig. 7C). The NAADP analog Ned-19 [42] was also found to be inactive in this preparation. Three separate lots of Ned-19 were tested on S. purpuratus egg homogenates, and concentrations of Ned-19 up to 1.6 μM, when pre-incubated with the homogenate for 2–3 min, failed to inhibit Ca2+ release in response to added NAADP (data not shown). Ned-19 at concentrations up to 10 μM similarly failed to inhibit the binding of [32P]NAADP to S. purpuratus membranes in the competition ligand binding assay (data not shown).
2.7 Structure activity relationship in a mammalian system
In sea urchin eggs, substitution of NAADP at the 4-position of the nicotinic acid resulted in the loss of agonist potency for both Ca2+ release and ligand binding, whereas substitution at the 5-position was tolerated [28]. To determine the effects of modification of NAADP at the 4- and 5-position of nicotinic acid in a mammalian system, we constructed concentration response curves for NAADP analogs (2–5) modified at the 4- and 5-position of the nicotinic acid moiety.
In SKBR3 cells the photolysis of caged 4-methyl-NAADP (2) elicited an optimal response at a pipette concentration of 100 nM (Fig. 8). The evoked Ca2+ response after photolysis of caged 4-methyl-NAADP (2) showed concentration dependence similar to that of caged NAADP (Fig. 8). Although uncaged 4-methyl-NAADP (2) is approximately equipotent with uncaged NAADP (1), the magnitude of Ca2+ release at optimal concentration of (2) is approximately 50% lower than that elicited by uncaged NAADP (1).
Interestingly, the maximal response observed after the photolysis of caged 5-methyl-NAADP (3) was at a pipette concentration of 10 μM, indicating that it is 100-fold less potent than the parent compound NAADP (1). As shown in Fig. 8, the evoked changes in cytosolic Ca2+ concentration increased in a concentration dependent manner that exhibited a maximal response at 10 μM. Above this concentration, the evoked signal gradually diminished. In addition, we tested two more analogs modified at the 5-position of nicotinic acid to determine whether this modification reduced the potency of the analogs in the mammalian system. Both analogs, 5-amino-NAADP (4) and 5-thiomethyl-NAADP (5), elicited the maximal response at a pipette concentration of 100 nM but with a reduced efficacy (Fig. 8). The concentration responses of 5-amino-NAADP (4) and 5-thiomethyl-NAADP (5) had similar shapes to that of NAADP with 2-fold and 5-fold less efficacy, respectively. These data demonstrated that substitution at the 5-position of nicotinic acid of NAADP exhibits a similar bell shaped concentration response relationship but with significantly reduced efficacy of Ca2+ release.
3. Discussion
We report a chemo-enzymatic synthesis of four novel photolabile caged NAADP derivatives. Each of these compounds was synthesized in a single step from the common intermediate DMNPE-caged NAADP and a 4 or 5-substituted nicotinic acid derivative using the enzyme catalyzed pyridine base exchange reaction. The novel caged NAADP derivatives (2–5) were purified by anion exchange chromatography, shown to be homogeneous by HPLC, and were characterized using NMR and mass spectrometry (shown in Supplementary Material Figures S7-S10). Caged NAADP derivatives (2–5) were found to be stable during storage as solid dry powders at −80 °C, and were deprotected after 10 minutes of irradiation with UV light at identical amounts. Although these polar anionic compounds are not expected to traverse cell membranes, they can be delivered intracellularly in a controlled manner by microinjection, thus enabling the role of NAADP in its cellular environment and the underlying mechanism of NAADP/Ca2+ release to be investigated.
In our initial experiments, we observed intracellular Ca2+ release from SKBR3 cells in response to the photolysis of microinjected caged NAADP (1). In accord with previous observations [10, 11, 16, 18, 39], the concentration–response relationship was bell shaped, indicative of inhibition at high NAADP concentration. The concentration of microinjected (1) that evoked a maximum Ca2+ response was found to be 100 nM. This concentration was comparable to that previously reported to activate Ca2+ release in mammalian cells.
We next demonstrated that Ca2+ release in SKBR3 cells in response to photolysis of caged NAADP (1) showed similar pharmacological characteristics to the response to microinjected uncaged NAADP. The H+-ATPase pump inhibitor bafilomycin A abolished the response to photolysed NAADP, indicating that lysosome-like acidic stores are the dominant source of NAADP evoked Ca2+ release in SKBR3 cells. This agrees with the bulk of current evidence that NAADP targets acidic stores to trigger Ca2+ release [43]. However, since depletion of ER stores by thapsigargin or cyclopiazonic acid prior to NAADP uncaging reduced the response, ER stores must also be involved. The contribution of ER stores to the overall NAADP response was confirmed with reversal of the order of addition. NAADP uncaging prior to CPA or ATP addition reduced subsequent responses to CPA or ATP, showing reduction of ER stores. Involvement of the ryanodine receptor is suggested by the reduction of the NAADP response by tetracaine treatment. These data support the hypothesis that the ER is indirectly involved via Ca2+ induced Ca2+ release and that the initial Ca2+ signal raised or “triggered” by NAADP is dependent on acidic stores and is necessary for the ER contribution for the propagation of that signal. Cross-talk between calcium stores exists in many cell types [24, 43, 44] and it has been speculated that NAADP has a role in initiating rather than propagating calcium signals and that the initial signal is derived from NAADP-mediated release from acidic stores and amplified by ryanodine receptors through the process of Ca2+-induced Ca2+ release [11]. Our findings are consistent with this proposal.
Based on the average 15 μm size of SKBR3 cells[45], we estimate that we are microinjecting 1 to 10% of the cell volume. Due to the inability to measure the light at the plane of focus, we cannot directly determine the concentration of photolysed NAADP present in the cell. However, each flash must release only a small portion of the total, since subsequent flashes release more Ca2+ and a second train of flashes given following rest will again release more Ca2+. The local nature of the release is shown by the relaxation of the response in contrast to the sustained Ca2+ concentrations seen in some cells with microinjected NAADP. However, the amount of each analog relative to other analogs should be constant.
We report the effect of introducing substituents into the pyridine base ring of NAADP at the 4- or the 5-positions on the ability of the analog to induce Ca2+ release in a mammalian cell line (SKBR3) and compare it to a previous SAR study in sea urchin eggs to help understand NAADP receptor diversity across species (see Table 1). In sea urchin eggs, the 5-substituted nicotinic acid NAADP analogs were found to be well recognized by the receptor and elicited Ca2+ release at low concentrations, whereas the 4-substitued analogs were found to lose agonist potency [28]. In SKBR3 cells, we found that 4- and 5-substituted analogs both have Ca2+ ion mobilizing activity. 4-Methyl-NAADP (from uncaging of 2), which was found to be 2000-fold less potent than NAADP in sea urchin eggs, induced Ca2+ release at low nanomolar concentrations approximately equipotent with NAADP, but was twofold less effective than NAADP itself in eliciting maximal Ca2+ release from SKBR3 cells. Comparison of this particular analog in sea urchin eggs and in mammalian SKBR3 cells suggests a major difference between the two systems in terms of tolerance to substitution at the nicotinic acid 4-position. This difference was notable, since all the 4-substituted analogs tested in sea urchin eggs lost potency for Ca2+ release and receptor binding activity. The different behavior of 4-methyl-NAADP in sea urchin eggs and the mammalian cell line SKBR3 suggests differences in the binding site between species. However, it is important to note that the Ca2+ release studies are done in cellular homogenates of sea urchin eggs and with intact cells for the mammalian receptor. Recently, photoaffinity labeling of NAADP targets in homogenates of sea urchin eggs and of the mammalian cell lines SKBR3 and Jurkat showed different molecular masses of the photolabeled proteins [32, 46, 47]. This suggests that differences are inherent in the receptors themselves. The activity of other analogs with different substitutions at the 4-position will be investigated in future experiments in an attempt to produce more potent NAADP analogs for the mammalian system. The 5-substituted NAADP analogs were slightly less effective than NAADP and none were able to elicit more than 50% of the Ca2+ release produced by NAADP itself in SKBR3 cells. Their relative potencies are comparable in both systems, with the exception of 5-methyl-NAADP. 5-Methyl-NAADP was approximately equipotent with NAADP in sea urchin eggs [28] and its activity in SKBR3 seemed to be the opposite of its activity observed in sea urchin eggs. 5-Methyl-NAADP was 100-fold less potent than NAADP in SKBR3 compared to 2.3-fold less potent in sea urchin eggs. Likewise in SKBR3, while 5-methyl-NAADP was 100-fold less potent than NAADP, 5-amino-NAADP and 5-thiomethyl-NAADP were both tolerated with only two and five fold loss of efficacy respectively.
Table 1.
Sea urchina | Human SKBR3 cells | |||
---|---|---|---|---|
| ||||
Nicotinic acid substituent on NAADP | Fold increase in EC50 compared to NAADP | Agonist efficacy | Fold increase in [cmpd]optimum vs. [NAADP]optimum | Agonist efficacy |
5-Amino | 1.5 | Full | 1 | Partial |
5-Methyl | 2.3 | Full | 100 | Partial |
5-Thiomethyl | 5.0b | Partialb | 1 | Weak-partial |
4-Methyl | 2,200. | Partial | 1 | Partial |
Derived from Jain et al. [28].
Unpublished observations
BZ194 was reported to antagonize NAADP-mediated Ca2+ signaling via the type 1 ryanodine receptor in Jurkat T-lymphocytes [26]. The role of BZ194 in antagonizing NAADP-mediated Ca2+ release in SKBR3 cells seems to be through a different mechanism. Since lysosome-like acidic stores appeared to be the dominant source of NAADP evoked Ca2+ release in SKBR3 as demonstrated above, it suggests that NAADP does not to bind RyR directly but activates novel channels located on acidic stores and thus the antagonism effect by BZ194 is not likely to be directly via RyR. Another possibility is that BZ194 indeed modulates its antagonistic effect on NAADP-mediated Ca2+ release via RyR by inhibiting the propagation of Ca2+ signals. This is not likely because BZ194 exhibited a much larger inhibition compared to that caused by Ca2+ depletion from the ER or by tetracaine, and similar to that of bafilomycin A.
We find that the four simple substituted NAADP derivatives tested differ in activity between sea urchin and SKBR3 cells both with respect to relative potencies and with respect to efficacy. We also observe a difference between sea urchin and SKBR3 cells with respect to sensitivity to the antagonist BZ194. BZ194 did not show any antagonist activity for NAADP-mediated Ca2+ signaling nor show any binding affinity for the NAADP receptor in sea urchin egg homogenates. Our observations imply a different SAR with respect to recognition at the 4-position of the nicotinic acid moiety between sea urchin eggs and mammalian cells at least in SKBR3. They indicate that the NAADP receptor exhibits diversity across species and among tissues. They also suggest that further modifications at the 4- and 5-position of the nicotinic acid ring may lead to the development of reagents for future studies of the NAADP-induced Ca2+ release system, including potent agonists and photoaffinity labels that could be used for receptor localization and isolation in mammalian systems.
4. Materials and methods
4.1 General description
The following procedures were used in all reactions unless otherwise noted. Reactions were performed in clean oven-dried glassware. All light sensitive reactions were carried out in the dark and the products were protected with aluminum foil and stored at −80 °C. Reactions were stirred using Teflon-coated magnetic stir bars. Chemical reagents were purchased from either Sigma-Aldrich or Acros Organics and used as received. MnO2 was from EM Sciences-Darmstadt, Germany. All reagent grade solvents (acetone, ethanol, methanol, ethyl acetate, and hexane) were purchased from Pharmco-AAPER or EMD chemicals. All anhydrous solvents were purchased in sure seal bottles from Sigma-Aldrich. Bafilomycin A1 was purchased from LC Laboratories, thapsigargin from Calbiochem, CPA from Sigma-Aldrich, Lysotracker Red from Molecular Probes, and Fluo-4 from Invitrogen. Proton 1H NMR spectra were measured in CDCl3 or D2O and determined using either a Unity-400 spectrophotometer (400 mHz) or a Varian Inova-600 spectrophotometer (600 mHz). All chemical shifts are reported in the standard (δ) notation of parts per million (ppm) and were referenced to the residual proton signal of the deuterated solvent, and reported to the second decimal place. 31P NMR was recorded on a Unity-400 spectrophotometer (162 mHz) with 85 % H3PO4 as an external reference. High-resolution mass spectral analyses were carried out at the Ohio State Mass Spectrometry & Proteomics Facility using either ESI or MALDI-TOF mass spectrometry.
4.2 HPLC analysis
The system for analysis of nucleotides using AG MP-1 anion exchange chromatography in gradient of trifluoroacetic acid and water was originally described in Axelson et.al. [48].
Method 1: Analytical column
To monitor the progress of caging and base-exchange reactions and to determine the purity of caged NAADP and its derivatives after purification, a Bio-Rad Uno-Q column (7 × 35 mm, 1.3 ml of anion-exchange resin) fitted to a Bio-Rad BioLogic Duoflow HPLC apparatus was used. Samples were injected into a loop with a volume of 50 μl. The flow rate throughout was 3 ml/min. Sample concentration was roughly equal to1mg/ml. Solvent A: H2O; Solvent B: 100 mM aqueous TFA: detection at 254 nm. 1) Load/inject sample, 50μl; 2) Solvent A, 9 ml; 3) Linear gradient, 0–50 % solvent B formed over 30 ml; 4) Solvent B, 9 ml; 5) Solvent A, 9ml. The total volume of this procedure is 57 ml.
Method 2: Prep-scale column
For purification purpose following large scale synthesis reactions of caged NAADP and its derivatives, a glass column (1.5 × 11.5 cm) filled with Bio-Rad AG-MP 1ion-exchange resin was connected with a Bio-Rad BioLogic Duoflow HPLC apparatus was used. The sample was introduced using an injection loop with a volume of 5 ml. The flow rate throughout was 5 ml/min. The sample concentration was roughly equal to 5 mg/ml. Solvent A: H2O; Solvent B: 100 mM aqueous TFA: detection at 254 nm. 1) Load/inject sample, 5 ml; 2) Solvent A, 10 ml; 3) Linear gradient, 0–60 % solvent B formed over 120 ml; 4) Solvent B, 10 ml; 5) Solvent A, 10 ml. The total volume of this procedure is 155 ml.
4.3 Synthesis of NAADP analogs
Synthesis of 5-thiomethyl nicotinic acid
5-Bromonicotinic acid (1 g, 5 mmol), sodium thiomethoxide (385 mg, 5.5 mmol) (Sigma-Aldrich) and dimethylformamide (10 ml) were added to a 10–20 ml Biotage microwave reactor vial. The vial was properly capped and allowed to react for 24 hours at 200 °C. After this time, TLC clearly revealed the presence of starting material. Another portion of sodium thiomethoxide (385 mg, 5.5 mmol) was added and allowed to react for 24 hours at 200 °C. The reaction was now shown to be complete and the crude material was filtered through Celite. The Celite was washed with 100 ml of 50% methanol in dichloromethane (DCM). The filtrates were combined and the solvent was evaporated in vacuo. The resulting residue was purified by column chromatography on silica gel (97:2:1 DCM:MeOH: acetic acid) affording a white solid (480 mg, 57 %): TLC Rf 0.49 in DCM: MeOH: acetic acid (95:4:1), 1H NMR (400 mHz, CD3OD) δ 8.85 (s, 1H), 8.60 (s, 1H), 8.22 (s, 1H), 2.59 (s, 3H); 13C NMR (100 mHz, CD3OD) δ 151.1, 147.4, 135.9, 15.2. HRMS calcd for C7H7NO2S: 170.0276 (M+H), Found m/z: 170.0278 (M+H). Structure, NMR traces and HRMS shown in Figure S2.
Synthesis of 4,5–dimethoxy-2-nitroacetophenone
4,5-Dimethoxyacetophenone (3 g, 16.6 mmol) was added over 10 min to concentrated nitric acid (20 ml) cooled using an ice-bath. The solution was stirred for 1 h and then poured into cold water (200 ml) to precipitate the product. The product was collected by filtration and recrystallized from ethanol (1 g, 27%); 1H NMR (CDCl3, 600 MHz): δ 7.63 (s, 1H), 6.77 (s, 1H), 3.99 (s, 6H), 2.51 (s, 3H); mp found 130–133°C; reported mp 130–132 °C [49]. Structure and NMR shown in Figure S3.
Synthesis of 4,5-dimethoxy-2-nitroacetophenylhydrazone
4,5-Dimethoxy-2-nitroacetophenone (250 mg, 1 mmol) was dissolved in ethanol (15 ml); acetic acid (180 mg, 3 mmol) was added and the mixture was stirred for 10 min at room temperature. Hydrazine monohydrate (160 mg, 5 mmol) was added and the resulting solution was refluxed for 3 h. After cooling to room temperature, the solvent was evaporated under reduced pressure and the crude product was partitioned between water and chloroform several times. The chloroform was evaporated and the product was recrystallized from toluene and dried under vacuum to give a yellow powder (200 mg, 76%). 1H NMR (CDCl3, 600 MHz): δ 7.59 (s, 1H), 6.85 (s, 1H), 5.37 (bs, 2H), 3.95 (s, 6H), 2.01(s, 3H). Structure and NMR shown in Figure S4.
Synthesis of DMNPE-caged NADP
A solution of NADP (74.4 mg, 0.1 mmol) in water (3 ml) was adjusted to pH 4 with NaOH (1.0 M) and placed in a 10 ml reaction vial. 4,5-Dimethoxy-2-nitroacetophenylhydrazone (0.2 g, 0.84 mmol) in chloroform (2 ml) was stirred in a separate reaction vial with MnO2 (0.8 g, 8.4 mmol, EM Sciences, Darmstadt, Germany) for 10 min in the dark. The resulting dark red chloroform solution of 4,5-dimethoxy-2-nitroacetophenyldiazoethane was filtered directly into the NADP solution. The biphasic mixture was stirred vigorously for 10 h, and the chloroform layer was removed and replaced by fresh solution of the diazoethane derivative. The reaction was stirred overnight and monitored by HPLC to show complete consumption of NADP within 24 h. The organic phase was removed and the aqueous layer purified by HPLC Method 2 using AG MP-1 resin developed with a gradient of water and TFA (0.1 M) (RT = 18 min, 45% TFA). The fractions were collected, neutralized to pH 7, and lyophilized to give a yellowish product (45 mg, 47%). 1H NMR (D2O, 600 MHz): δ 9.34 (s, 1H), 9.18 (s, 1H), 8.86 (d, J = 7.8 Hz, 1H), 8.35 (d, J = 29.4 Hz, 1H), 8.26 (d, J = 14.4 Hz, 1H), 8.21 (t, J = 6 Hz, 1H), 7.44 (d, J = 27.6 Hz, 1H), 6.93 (d, J = 6.6 Hz, 1H), 6.09 (d, J = 5.4 Hz, 1H), 6.03 (d, J = 5.4 Hz, 1H), 5.87 (d, J = 6 Hz, 1H), 5.63(m, 1H), 5.1 (m, 1H), 4.53 (m, 1H), 4.48 (m, 1H), 4.4(m, 2H), 4.24 (m, 1H), 4.15–3.95 (m, 4H), 3.78 (m, 6H), 1.35 (d, J = 6 Hz, 3H). 31P NMR (D2O, pH 7.4, 162 MHz): δ –.82, −10.49. Structure and NMR shown in Figure S5.
Synthesis of caged NAADP analogs
To a solution of DMNPE-caged NADP (19 mg, 0.02 mmol) in water (3 ml) was added a solution of one of these; nicotinic acid, 4-methyl nicotinic acid, 5-methyl nicotinic acid, 5-amino nicotinic acid, or 5-thiomethyl nicotinic acid ( 0.2 mmol) in water (3 ml). The mixture was adjusted to pH 4 and stirred at 37 °C in the presence of Aplysia ADP-ribosyl cyclase (150 μl, 0.2 g/ml) described in [50] and [51]. The reaction was monitored by HPLC and showed complete loss of DMNPE-caged NADP and formation of caged NAADP analog after 24 h. The product was purified by HPLC Method 2 using anion exchange AG MP-1 and developing the chromatography with an aqueous TFA gradient (0.1 M). The fractions were collected, neutralized to pH 7, and lyophilized and stored at −80°C. The synthetic procedure and properties of each analog are reported in Table 2. The NMR data for each caged analog are given below. Structures, representative NMR spectra, HPLC traces, and HRMS are provided in Supplementary Material Figures S6–S10.
Table 2.
Initial Reactant | Base Exchanged | Source of Base | Caged Product | Retention Time of Product | Yield |
---|---|---|---|---|---|
Caged NADP | Nicotinic Acid; 24.6 mg | Sigma-Aldrich | Caged NAADP (1) | 24 min, 53.5% TFA | 10 mg, 52% |
4-Methyl Nicotinic Acid; 27.4 mg | Maybridge | Caged 4-Methyl NAADP (2) | 24.5 min, 54% TFA | 9.5 mg, 49% | |
5-Methyl Nicotinic Acid; 27.4 mg | Acros | Caged 5-Methyl NAADP (3) | 23 min, 53% TFA | 11 mg, 57% | |
5-Amino Nicotinic Acid; 27.6 mg | Combi-Blocks Inc | Caged 5-Amino NAADP (4) | 23.5 min, 53% TFA | 10 mg, 52% | |
5-Thiomethyl Nicotinic Acid; 33.8 mg | Synthesized (see description) | Caged 5-Thiomethyl NAADP (5) | 24.7 min, 54% TFA | 10 mg, 50% |
Caged NAADP (1)
1H NMR (D2O, 600 MHz): δ 9.40 (s, 1H), 9.23 (s, 1H), 8.96 (d, J = 7.8 Hz, 1H), 8.36 (d, J = 24 Hz, 1H), 8.26 (d, J = 14.4 Hz, 1H), 8.21 (t, J = 6 Hz, 1H), 7.44 (d, J = 24 Hz, 1H), 6.93 (d, J = 7.8, 1H), 6.1 (d, J = 5.4 Hz, 1H), 6.03 (d, J = 5.4 Hz, 1H), 5.87 (d, J = 6 Hz, 1H), 5.64 (m, 1H), 5.1 (m, 1H), 4.54 (m, 1H), 4.47 (m, 1H), 4.4 (m, 2H), 4.25 (m, 1H), 4.16–4.0 (m, 4H), 3.79 (m, 6H), 1.35 (t, J = 3.6 Hz, 3H). 31P NMR (D2O, pH 7.4, 162 MHz): δ –0.96, −10.77. HRMS calcd for C31H39N7O22P3+: 954.14, Found m/z: 954.11 (M+Na).
Caged 4-Methyl NAADP (2)
1H NMR (D2O, 600 MHz): δ 8.98 (s, 1H), 8.85 (s, 1H), 8.65 (s, 1H), 8.33 (d, J = 23.4 Hz, 1H), 8.15 (d, J = 12 Hz, 1H), 7.44 (d, J = 46.2 Hz, 1H), 6.92 (d, J = 10.8, 1H), 5.96 (m, 2H), 5.82 (d, J = 6 Hz, 1H), 5.69 (m, 1H), 5.13 (m, 1H), 4.54 (m, 1H), 4.44(m, 1H), 4.37 (m, 2H), 4.23 (m, 1H), 4.15–4.02 (m, 4H), 3.82 (m, 6H), 2.49 (s, 3H), 1.37 (t, J = 5.4 Hz, 3H). 31P NMR (D2O, pH 7.4, 162 MHz): δ –0.80, −10.04. HRMS calcd for C32H41N7O22P3+: 968.15, Found m/z: 968.12 (M+Na).
Caged 5-Methyl NAADP (3)
1H NMR (D2O, 600 MHz): δ 8.96 (s, 1H), 8.66 (t, J = 9.6 Hz, 2H), 8.31 (s, 1H), 7.95 (d, J = 15.6 Hz, 1H), 7.38 (d, J = 42 Hz, 1H), 6.91 (d, J = 12, 1H), 5.93 (s, 1H), 5.81 (m, 2H), 5.72 (m, 1H), 5.1 (m, 1H), 4.62(m, 1H), 4.45 (m, 1H), 4.36 (m, 3H), 4.23–4.17 (m, 4H), 3.88 (m, 6H), 2.49 (s, 3H), 1.43 (t, J = 5.4 Hz, 3H). 31P NMR (D2O, pH 7.4, 162 MHz): δ –0.85, −10.12. HRMS calcd for C32H41N7O22P3+: 968.15, Found m/z: 968.17 (M+Na).
Caged 5-Amino NAADP (4)
1H NMR (D2O, 600 MHz): δ 8.54 (d, J = 8.4 Hz, 1H), 8.45 (s, 1H), 8.40 (s, 1H), 8.35 (s, 1H), 8.27 (d, J = 13.8 Hz, 1H), 7.95 (s, 1H), 7.47 (d, J = 27 Hz, 1H), 6.96 (d, J = 9.6 Hz, 1H), 6.03 (d, J = 5.4 Hz, 1H), 5.87 (m, 2H), 5.66 (m, 1H), 5.1 (m, 1H), 4.53 (m, 1H), 4.41 (m, 1H), 4.38(m, 2H), 4.25 (m, 1H), 4.16–4.02 (m, 4H), 3.84 (m, 6H), 1.37 (d, J = 6 Hz, 3H). 31P NMR (D2O, pH 7.4, 162 MHz): δ –1.14, −10.88. HRMS calcd for C31H41N8O22P3+: 969.15, Found m/z: 969.23 (M+).
Caged 5-Thiomethyl NAADP (5)
1H NMR (D2O, 600 MHz): δ 9.11 (s, 1H), 8.87(s, 1H), 8.75 (t, J = 2.4 Hz, 1H), 8.41 (d, J = 6 Hz, 1H), 8.32 (d, J = 11.4 Hz, 1H), 7.5 (d, J = 23.4 Hz, 1H), 7.0 (d, J = 11.4 Hz, 1H), 6.09 (m, 2H), 5.92 (d, J = 5.4 Hz, 1H), 5.7 (m, 1H), 5.1 (m, 1H), 4.58 (m, 1H), 4.52 (m, 1H), 4.45 (m, 2H), 4.25 (m, 1H), 4.13–4.05 (m, 4H), 3.85 (m, 6H), 2.65 (s, 3H), 1.41 (d, J = 6.6 Hz, 3H). 31P NMR (D2O, pH 7.4, 162 MHz): δ –.1.17, −10.03. HRMS calcd for C32H41N7O22P3S+: 1000.12, Found m/z: 1000.14 (M+Na).
Synthesis of BZ194
BZ194 was synthesized according to the original procedures described in [26]. The melting point and spectroscopic properties of the compound we isolated were in close agreement with the properties reported.
4.4 Cell culture
Human adeno-carcinoma SKBR3 cell line was purchased from ATCC (HTB-30) and cultured in phenol red-free McCoy’s 5a medium (Fisher) with 10% fetal calf serum (Atlanta Biologicals) and split twice weekly.
4.5 Microinjection
Forty-eight hours prior to injection and live cell imaging experiments, SKRB3 cells were plated on glass bottom dishes (Mattek P50G-1.5-30-F) in phenol red-free McCoy’s 5a medium. A Narishige IM-9B microinjector controlled by a Narishige NAI-2N micromanipulator was used for microinjection of single SKBR3 cells. Caged NAADP and its derivatives were diluted to their final concentration in intracellular buffer (10 mM Hepes, 128 mM KCl, 20 mM NaCl, 1mM MgCl2, and 0.1 mM EGTA, pH 7.2) along with 200 μM of the Ca2+ sensitive dye Fluo-4 and loaded (2μl) into glass micropipette (World Precision Instruments). Cells were co-injected with a mixture of the indicated concentration of caged NAADP or its analog and the Ca2+ sensitive dye. In co-injection experiments, BZ194 was dissolved in DMSO and mixed with the stock solution containing caged NAADP. A volume of approximately 1 nl was injected into each cell.
4.6 Microscopy and analysis of [Ca2+]i
After a short rest to allow the cells to recover from microinjection, determination of [Ca2+]i was performed using digital fluorescence imaging microscopy with a monochronometer-based system and high speed CCD camera (TILL-Photonics). Cells were alternately excited at 488± 15 nm and the fluorescence emission was collected through a 510 ± 25-nm band pass filter (Chroma). Photolytic release of NAADP or analog was achieved using a pulsed xenon arc lamp fed to a dual port epifluorescence condenser using a fiber-optic guide (Rapp Optoelectronic JML-G2). Eight to ten 80-J, 0.5-ms flashes of UV light (360 ± 7.5 nm) were reflected onto the plane of focus using a DM400 dichroic mirror and Super Fluor 40×, 1.3 NA oil immersion objective
4.7 Analysis of NAADP signaling and binding in sea urchin egg homogenates
This was performed according to the procedure of Aarhus et al. [36]. Briefly, testing of NAADP or analogs for Ca2+ release on cell free receptor systems in the presence and absence of antagonist was performed on homogenates (1.25% v/v) prepared from sea urchin eggs (Strongylocentrotus purpuratus) diluted with intracellular medium containing 250 mM potassium gluconate buffer (pH 7.2), 0.5 mM ATP, 4 mM creatinine phosphate, creatinine (phospho)kinase and 3 μM fluorescent indicator, Fluo-3. The dilutions and all experiments were conducted at 17 °C. Fluorescence was measured using a fluorescence plate reader (excitation 490 nm and emission 535 nm). In some cases, solutions of caged analogs were irradiated with UV light prior to testing. The competitive binding assays were done in triplicate in 96 well filter plates containing the cell free sea urchin egg homogenate and constant concentration of radioligand [32P]NAADP (0.2 nM). The competitor and [32P]NAADP were incubated simultaneously with the sea urchin egg homogenate for 90 min at 4 °C. The homogenate was filtered and washed and the radioactivity retained on the filter was determined by liquid scintillation [28].
4.8 Uncaging efficiency
To determine whether there were differences in the efficiency of uncaging for the synthesized analogs, we measured their photolysis rate under identical, controlled conditions. Stock solutions of pure caged NAADP analogs (685 μM) were prepared in intracellular buffer. A photolysis reaction was run for each analog simultaneously by placing 50 μl of the stock solution on a porcelain spot-test plate under a handheld short wave UV lamp (254 nm) for 10 minutes. Each sample (50 μl) was then analyzed by HPLC under the same conditions as for prior analyses. The analogs were partially uncaged and NAADP or its derivative peak was observed after the photolysis reaction. The ratio of the photolysed uncaged portion to the intact caged portion was calculated as a percentage. For UV treatment in experiments with sea urchin egg homogenates, compounds were irradiated in a Rayonet photochemical reactor (Southern New England Ultraviolet Co.) for 2 minutes [36].
Supplementary Material
Acknowledgments
Thank you to Dr. Surya Nauli for the use of his microinjection apparatus. This work was supported by a University of Toledo Interdisciplinary Research Initiation Program Grant and by NIH Grant # GM100444-01.
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
- 1.Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4:517–529. doi: 10.1038/nrm1155. [DOI] [PubMed] [Google Scholar]
- 2.Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol. 2000;1:11–21. doi: 10.1038/35036035. [DOI] [PubMed] [Google Scholar]
- 3.Clapham DE. Calcium Signaling. Cell. 2007;131:1047–1058. doi: 10.1016/j.cell.2007.11.028. [DOI] [PubMed] [Google Scholar]
- 4.Berridge MJ. Inositol trisphosphate and calcium signalling. Nature. 1993;361:315–325. doi: 10.1038/361315a0. [DOI] [PubMed] [Google Scholar]
- 5.Lee HC. Mechanisms of calcium signaling by cyclic ADP-ribose and NAADP. Physiol Rev. 1997;77:1133–1164. doi: 10.1152/physrev.1997.77.4.1133. [DOI] [PubMed] [Google Scholar]
- 6.Guse AH. Regulation of Calcium Signaling by the Second Messenger Cyclic Adenosine Diphosphoribose (cADPR) Curr Mol Med. 2004;4:239–248. doi: 10.2174/1566524043360771. [DOI] [PubMed] [Google Scholar]
- 7.Fliegert R. Regulation of calcium signalling by adenine-based second messengers. Biochem Soc Trans. 2007;35:109–114. doi: 10.1042/BST0350109. [DOI] [PubMed] [Google Scholar]
- 8.Lee HC. Cyclic ADP-ribose and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) as Messengers for Calcium Mobilization. J Biol Chem. 2012;287:31633–31640. doi: 10.1074/jbc.R112.349464. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Clapper DL, Walseth TF, Dargie PJ, Lee HC. Pyridine nucleotide metabolites stimulate calcium release from sea urchin egg microsomes desensitized to inositol trisphosphate. J Biol Chem. 1987;262:9561–9568. [PubMed] [Google Scholar]
- 10.Lee HC, Aarhus R. A Derivative of NADP Mobilizes Calcium Stores Insensitive to Inositol Trisphosphate and Cyclic ADP-ribose. J Biol Chem. 1995;270:2152–2157. doi: 10.1074/jbc.270.5.2152. [DOI] [PubMed] [Google Scholar]
- 11.Cancela JM, Churchill GC, Galione A. Coordination of agonist-induced Ca2+-signalling patterns by NAADP in pancreatic acinar cells. Nature. 1999;398:74–76. doi: 10.1038/18032. [DOI] [PubMed] [Google Scholar]
- 12.Bak J, Billington RA, Timar G, Dutton AC, Genazzani AA. NAADP receptors are present and functional in the heart. Curr Biol. 2001;11:987–990. doi: 10.1016/s0960-9822(01)00269-x. [DOI] [PubMed] [Google Scholar]
- 13.Bak J, White P, Timár G, Missiaen L, Genazzani AA, Galione A. Nicotinic acid adenine dinucleotide phosphate triggers Ca2+ release from brain microsomes. Curr Biol. 1999;9:751–754. doi: 10.1016/s0960-9822(99)80335-2. [DOI] [PubMed] [Google Scholar]
- 14.Cheng J, Ysufi ANK, Thompson MA, Chini EN, Grande JP. Nicotinic Acid Adenine Dinucleotide Phosphate: A New Ca2+ Releasing Agent in Kidney. J Amer Soc Nephrology. 2001;12:54–60. doi: 10.1681/ASN.V12154. [DOI] [PubMed] [Google Scholar]
- 15.Langhorst MF, Schwarzmann N, Guse AH. Ca2+ release via ryanodine receptors and Ca2+ entry: major mechanisms in NAADP-mediated Ca2+ signaling in T-lymphocytes. Cell Signal. 2004;16:1283–1289. doi: 10.1016/j.cellsig.2004.03.013. [DOI] [PubMed] [Google Scholar]
- 16.Berg I, Potter BVL, Mayr GW, Guse AH. Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP+) Is an Essential Regulator of T-Lymphocyte Ca2+-Signaling. J Cell Biol. 2000;150:581–588. doi: 10.1083/jcb.150.3.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Lee HC. Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP)-mediated Calcium Signaling. J Biol Chem. 2005;280:33693–33696. doi: 10.1074/jbc.R500012200. [DOI] [PubMed] [Google Scholar]
- 18.Chini EN, Beers KW, Dousa TP. Nicotinate Adenine Dinucleotide Phosphate (NAADP) Triggers a Specific Calcium Release System in Sea Urchin Eggs. J Biol Chem. 1995;270:3216–3223. doi: 10.1074/jbc.270.7.3216. [DOI] [PubMed] [Google Scholar]
- 19.Chini EN, Dousa TP. Nicotinate-adenine dinucleotide phosphate-induced Ca2+-release does not behave as a Ca2+-induced Ca2+-release system. Biochem J. 1996;316:709–711. doi: 10.1042/bj3160709. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Galione A, Churchill GC. Interactions between calcium release pathways: multiple messengers and multiple stores. Cell Calcium. 2002;32:343–354. doi: 10.1016/s0143416002001902. [DOI] [PubMed] [Google Scholar]
- 21.Lee HC, Aarhus R. Functional visualization of the separate but interacting calcium stores sensitive to NAADP and cyclic ADP-ribose. J Cell Sci. 2000;113:4413–4420. doi: 10.1242/jcs.113.24.4413. [DOI] [PubMed] [Google Scholar]
- 22.Churchill GC, Okada Y, Thomas JM, Genazzani AA, Patel S, Galione A. NAADP Mobilizes Ca2+ from Reserve Granules, Lysosome-Related Organelles, in Sea Urchin Eggs. Cell. 2002;111:703–708. doi: 10.1016/s0092-8674(02)01082-6. [DOI] [PubMed] [Google Scholar]
- 23.Berridge G, Dickinson G, Parrington J, Galione A, Patel S. Solubilization of Receptors for the Novel Ca2+-mobilizing Messenger, Nicotinic Acid Adenine Dinucleotide Phosphate. J Biol Chem. 2002;277:43717–43723. doi: 10.1074/jbc.M203224200. [DOI] [PubMed] [Google Scholar]
- 24.Macgregor A, Yamasaki M, Rakovic S, Sanders L, Parkesh R, Churchill GC, Galione A, Terrar DA. NAADP Controls Cross-talk between Distinct Ca2+ Stores in the Heart. J Biol Chem. 2007;282:15302–15311. doi: 10.1074/jbc.M611167200. [DOI] [PubMed] [Google Scholar]
- 25.Hohenegger M, Suko J, Gscheidlinger R, Drobny H, Zidar A. Nicotinic acid-adenine dinucleotide phosphate activates the skeletal muscle ryanodine receptor. Biochem J. 2002;367:423–431. doi: 10.1042/BJ20020584. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Dammermann W, Zhang B, Nebel M, Cordiglieri C, Odoardi F, Kirchberger T, Kawakami N, Dowden J, Schmid F, Dornmair K, Hohenegger M, Flügel A, Guse AH, Potter BVL. NAADP-mediated Ca2+ signaling via type 1 ryanodine receptor in T cells revealed by a synthetic NAADP antagonist. Proc Natl Acad Sci USA. 2009;106:10678–10683. doi: 10.1073/pnas.0809997106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Trabbic C, Walseth TF, Slama JT. Synthesis, Biochemical Activity, and Structure-Activity Relationship Among Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Analogs. Messenger. 2012;1:108–120. [Google Scholar]
- 28.Jain P, Slama JT, Perez-Haddock LA, Walseth TF. Nicotinic Acid Adenine Dinucleotide Phosphate Analogues Containing Substituted Nicotinic Acid: Effect of Modification on Ca2+ Release. J Med Chem. 2010;53:7599–7612. doi: 10.1021/jm1007209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Lee HC, Aarhus R. Structural Determinants of Nicotinic Acid Adenine Dinucleotide Phosphate Important for Its Calcium-mobilizing Activity. J Biol Chem. 1997;272:20378–20383. doi: 10.1074/jbc.272.33.20378. [DOI] [PubMed] [Google Scholar]
- 30.Billington RA, Tron GC, Reichenbach S, Sorba G, Genazzani AA. Role of the nicotinic acid group in NAADP receptor selectivity. Cell Calcium. 2005;37:81–86. doi: 10.1016/j.ceca.2004.06.009. [DOI] [PubMed] [Google Scholar]
- 31.Morgan AJ, Galione A. Investigating cADPR and NAADP in intact and broken cell preparations. Methods. 2008;46:194–203. doi: 10.1016/j.ymeth.2008.09.013. [DOI] [PubMed] [Google Scholar]
- 32.Lin-Moshier Y, Walseth TF, Churamani D, Davidson SM, Slama JT, Hooper R, Brailoiu E, Patel S, Marchant JS. Photoaffinity Labeling of Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Targets in Mammalian Cells. J Biol Chem. 2012;287:2296–2307. doi: 10.1074/jbc.M111.305813. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Parkesh R, Vasudevan SR, Berry A, Galione A, Dowden J, Churchill GC. Chemo-enzymatic synthesis and biological evaluation of photolabile nicotinic acid adenine dinuclotide phosphate (NAADP+) Org & Biomol Chem. 2007;5:441–443. doi: 10.1039/b617344f. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Lee HC, Aarhus R, Gee KR, Kestner T. Caged Nicotinic Acid Adenine Dinucleotide Phosphate: Synthesis and Use. J Biol Chem. 1997;272:4172–4178. doi: 10.1074/jbc.272.7.4172. [DOI] [PubMed] [Google Scholar]
- 35.Aarhus R, Graeff RM, Dickey DM, Walseth TF, Hon CL. ADP-ribosyl Cyclase and CD38 Catalyze the Synthesis of a Calcium-mobilizing Metabolite from NADP. J Biol Chem. 1995;270:30327–30333. doi: 10.1074/jbc.270.51.30327. [DOI] [PubMed] [Google Scholar]
- 36.Aarhus R, Dickey DM, Graeff RM, Gee KR, Walseth TF, Lee HC. Activation and Inactivation of Ca Release by NAADP. J Biol Chem. 1996;271:8513–8516. doi: 10.1074/jbc.271.15.8513. [DOI] [PubMed] [Google Scholar]
- 37.Schrlau MG, Brailoiu E, Patel S, Gogotsi Y, Dun NJ, Bau HH. Carbon nanopipettes characterize calcium release pathways in breast cancer cells. Nanotechnology. 2008;19:325102–325102. doi: 10.1088/0957-4484/19/32/325102. [DOI] [PubMed] [Google Scholar]
- 38.Brailoiu E, Churamani D, Cai X, Schrlau MG, Brailoiu GC, Gao X, Hooper R, Boulware MJ, Dun NJ, Marchant JS, Patel S. Essential requirement for two-pore channel 1 in NAADP-mediated calcium signaling. J Cell Biol. 2009;186:201–209. doi: 10.1083/jcb.200904073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Albrieux M, Lee HC, Villaz M. Calcium Signaling by Cyclic ADP-ribose, NAADP, and Inositol Trisphosphate Are Involved in Distinct Functions in Ascidian Oocytes. J Biol Chem. 1998;273:14566–14574. doi: 10.1074/jbc.273.23.14566. [DOI] [PubMed] [Google Scholar]
- 40.Malgaroli A, Milani D, Meldolesi J, Pozzan T. Fura-2 Measurement of Cytosolic Free Ca 2+ in Monolayers and Suspensions of Various Types of Animal Cells. J Cell Biol. 1987;105:2145–2155. doi: 10.1083/jcb.105.5.2145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Dammermann W, Guse AH. Functional Ryanodine Receptor Expression Is Required for NAADP-mediated Local Ca2+ Signaling in T-lymphocytes. J Biol Chem. 2005;280:21394–21399. doi: 10.1074/jbc.M413085200. [DOI] [PubMed] [Google Scholar]
- 42.Naylor E, Arredouani A, Vasudevan SR, Lewis AM, Parkesh R, Mizote A, Rosen D, Thomas JM, Izumi M, Ganesan A, Galione A, Churchill GC. Identification of a chemical probe for NAADP by virtual screening. Nat Chem Biol. 2009;5:220–226. doi: 10.1038/nchembio.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Churchill GC, Galione A. NAADP induces Ca2+ oscillations via a two-pool mechanism by priming IP3- and cADPR-sensitive Ca2+ stores. EMBO J. 2001;20:2666–2671. doi: 10.1093/emboj/20.11.2666. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Cancela JM, Van Coppenolle F, Galione A, Tepikin AV, Petersen OH. Transformation of local Ca2+ spikes to global Ca2+ transients: the combinatorial roles of multiple Ca2+ releasing messengers. The EMBO journal. 2002;21:909–919. doi: 10.1093/emboj/21.5.909. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Coumans FA, van Dalum G, Beck M, Terstappen LW. Filter characteristics influencing circulating tumor cell enrichment from whole blood. PloS one. 2013;8:e61770. doi: 10.1371/journal.pone.0061770. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Walseth TF, Lin-Moshier Y, Jain P, Ruas M, Parrington J, Galione A, Marchant JS, Slama JT. Photoaffinity Labeling of High Affinity Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP)-Binding Proteins in Sea Urchin Egg. J Biol Chem. 2012;287:2308–2315. doi: 10.1074/jbc.M111.306563. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Walseth TF, Lin-Moshier Y, Weber K, Marchant JS, Slama JT, Guse AH. Nicotinic Acid Adenine Dinucleotide 2-Phosphate (NAADP) Binding Proteins in T-Lymphocytes. Messenger. 2012;1:86–94. doi: 10.1166/msr.2012.1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Axelxon JT, Bodley JW, Walseth TF. A volatile liquid chromatography system for nucleotides. Anal Biochem. 1981;116:357–360. doi: 10.1016/0003-2697(81)90371-7. [DOI] [PubMed] [Google Scholar]
- 49.Wilcox M, Viola RW, Johnson KW, Billington AP, Carpenter BK, McCray JA, Guzikowski AP, Hess GP. Synthesis of photolabile precursors of amino acid neurotransmitters. J Org Chem. 1990;55:1585–1589. [Google Scholar]
- 50.Munshi C, Lee HC. High-level expression of recombinant Aplysia ADP-ribosyl cyclase in Pichia pastoris by fermentation. Protein Expr Purif. 1997;11:104–110. doi: 10.1006/prep.1997.0773. [DOI] [PubMed] [Google Scholar]
- 51.Lee HC, Graeff RM, Munshi CB, Walseth TF, Aarhus R. Large-scale purification of Aplysia ADP-ribosylcyclase and measurement of its activity by fluorimetric assay. Methods Enzymol. 1997;280:331–340. doi: 10.1016/s0076-6879(97)80124-3. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.